Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on TVTX.
Travere Therapeutics Inc. (TVTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 3,752,574 | $213,183,729 | -10% | 3.2% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 2,569,356 | $145,965,114 | +163% | 0.2% |
| 3. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 2,179,069 | $123,792,910 | +48% | 6.04% |
| 4. | Kynam Capital Derrick Tang | 2,000,000 | $113,620,000 | +28% | 6.28% |
| 5. | Renaissance Technologies Jim Simons | 1,833,079 | $104,137,218 | -7% | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | $89,250.00 | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | $76,564.50 | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | $129,049.50 | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | $51,118.00 | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | $73,950.00 | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $63.61 | 47,746 | $3,037,247.20 | 98,197 | 2026-09-16 | Filing | |
| $63.12 | 65,104 | $4,109,397.03 | 145,943 | 2026-09-16 | Filing | |
| $65.31 | 270 | $17,633.70 | 98,197 | 2026-09-15 | Filing | |
| $63.65 | 3,000 | $190,952.40 | 98,467 | 2026-09-15 | Filing | |
| $62.66 | 29,021 | $1,818,316.56 | 101,467 | 2026-09-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,324,191 | $643,299,225 | 0.26% | |
| 2. | 8,020,663 | $455,653,851 | 0.01% | |
| 3. | 7,096,614 | $403,158,609 | 0.02% | |
| 4. | 4,568,341 | $259,527,476 | 0.02% | |
| 5. | 4,256,224 | $241,796,085 | 0.01% |
News See All
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2026 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2026 Earnings Call Transcript May 4, 2026Travere Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.24203.
Billionaire Joe Edelman's 10 Stock Picks with Huge Upside Potential
In this article, we discuss the Billionaire Joe Edelman's Stock Picks with Huge Upside Potential.
Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on TVTX.
10 Stocks With Monster Returns
Ten stocks boasted strong double- to triple-digit gains last week, outperforming a mostly optimistic US market amid US and Iran’s efforts for a peace deal.
10 Overlooked Growth Stocks to Buy Now
In this article, we will discuss the 10 Overlooked Growth Stocks to Buy Now. On April 14, Tom Lee, Fundstrat's Head of Research, joined CNBC's 'Power Lunch' to discuss his outlook on equities.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 19, Travere Therapeutics Inc.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory
We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX.
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026.
Hedge Fund Resource Center